Search
Ciltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigational[A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744]
Elivaldogene autotemcel
go.drugbank.com/drugs/DB16746Approved[L40298] In September 2022, Skysona was approved by the FDA.[L43247]
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational[A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis.
Articaine
go.drugbank.com/drugs/DB09009ApprovedInvestigationalArticaine is a dental local anesthetic. Articaine is widely used around the world and is the most popular local anesthetic in many European countries.
Mixtures: SEPTANEST® ADRENALINEE AU 1/100.000Glucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigational[L39855] Glucarpidase was first approved by the FDA in January 2012,[A7476] followed by the European Commission's approval in January 2022.[L39865] It is marketed as VORAXAZE.
Pacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigationalPacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment
Zavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigational[A258190,A258195] In March 2023, the FDA approved the use of zavegepant nasal spray for the acute treatment of migraine with or without aura in adults.
CYT007-TNFQb
go.drugbank.com/drugs/DB05758ExperimentalCYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis.
CTS-21166
go.drugbank.com/drugs/DB06073InvestigationalCTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far.